Genmab — August 2020
-
Ved ikke hvor meget højere det kan blive. Men Genmab fik taget dem i røveren (GSK), idet rygterne vil vide, at Genmab fik retten til at arbejde med stoffer rettet imod CD20 igen i forbindelse med overdragelsen af Arzerra til Novartis. Det kan vi være glade for i dag.
-
John Carroll
@JohnCendpts
·
7 m
Now here's the funny thing. $NVS is pricing their MS drug at $89K, vs $65K for Roche's Ocrevus. They're charging for the convenience -- and savings -- that come from avoiding infusion centers.
Will that fly? https://twitter.com/JohnCendpts/status/1296518965330673664 -
Genmab Announces Plan to Transition Arzerra
(ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
technologies
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind